SYNTEX GANCICLOVIR NDA APPROVAL REQUIREMENTS ARE SUBJECT OF FDA-NIAID TALKS
The clinical requirements for Syntex' Cytovene (ganciclovir) NDA for the treatment of AIDS-related CMV retinitis are the subject of discussions between FDA topside and National Institute of Allergy and Infectious Diseases Director Anthony Fauci. At a Feb. 7 hearing before the Senate Labor & Human Resources Committee, chaired by Sen. Kennedy (D-Mass.), FDA Commissioner Young said he contacted NIAID's Fauci "last week" about finding a way to substantiate the largely anecdotal safety and efficacy data available to support the ganciclovir NDA. The purpose of his communications with Fauci, Young said, is "to bring in some of these investigators who have this evidence . . . and have that evidence put in the file at FDA and see whether we've got enough information to make an evaluation." Young told the committee he would report on the outcome of his discussions with Fauci. Ganciclovir has been available on a compassionate use basis since February 1985 and under a Treatment IND since last December ("The Pink Sheet" Dec. 5, T&G-6). In December, FDA also announced that Syntex and NIAID would initiate a controlled clinical study involving approximately 20 new enrollees per month. To date, no patients have been enrolled in the study. Unless early interim analyses of the study show conclusive results, the trial may require up to 180 patients and last as long as two years, NIAID is estimating.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth